CO9.2 - Bayesian model using bivariate efficacy-tolerability outcome in patients with angiosarcoma to determine the safe most successful dose of propranolol in combination with metronomic fixed-dose cyclophosphamide: PROPAN a Phase I-II sequential trial
Titel:
CO9.2 - Bayesian model using bivariate efficacy-tolerability outcome in patients with angiosarcoma to determine the safe most successful dose of propranolol in combination with metronomic fixed-dose cyclophosphamide: PROPAN a Phase I-II sequential trial
Auteur:
Foinet, E. Jouve, E. Salas, S. Blay, J. Chevreau, C. Le Cesne, A. Bompas, E. Bertucci, F. Kurtz, J. Isambert, N. Chaigneau, L. Micallef, J. Zohar, S.